Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 158.03 [7][8]. Core Views - The company has returned to growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items showing year-on-year increases of 5.4%, 1.9%, and 26.1% respectively [1]. - The company is expected to achieve steady growth in 2025, driven by improved domestic equipment update policies and ongoing global expansion efforts [1][4]. Summary by Sections Financial Performance - For 2024, the company reported revenue of RMB 103.00 billion, a year-on-year decline of 9.7%, with net profit attributable to the parent at RMB 12.62 billion, down 36.1% [1]. - In Q1 2025, the company achieved revenue of RMB 24.78 billion, with a gross margin of 49.9%, reflecting a 0.4 percentage point increase year-on-year [1]. Business Segments - Equipment Products: Revenue for 2024 was RMB 84.45 billion, down 14.9% year-on-year, but the RT business grew by 18.1% due to superior product performance [2]. - Maintenance Services: Revenue for 2024 was RMB 13.56 billion, up 26.8% year-on-year, with a gross margin of 63.4% [2]. Market Position - Domestic Market: Revenue in 2024 was RMB 80.34 billion, down 17.5% year-on-year, but the company maintained the highest market share in new imaging products in China [3]. - International Market: Revenue in 2024 was RMB 22.66 billion, up 35.1% year-on-year, with operations in over 85 countries [3]. Earnings Forecast and Valuation - The company is projected to have EPS of RMB 2.43, 2.93, and 3.53 for 2025, 2026, and 2027 respectively, with a target price based on a 65x PE ratio for 2025 [4][6].
联影医疗:1Q25业绩重回增长,看好全年发展-20250429